TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1982830
Drug: Intraperitoneal (i.p.)
Normalized name: Intraperitoneal Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal (i.p.) R‐EPO (170 +/‐ 42 U/kg/week) thrice weekly
Study: 45587
Drug: Floctafenine 200
Normalized name: floctafenine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Floctafenine 200 mg
Study: 343967
Drug: Oral meperidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral meperidine 75 mg
Study: 343967
Drug: Oral propoxyphene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propoxyphene 65 mg
Study: 30732471
Drug: Adjunctive anti-radiation
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive anti-radiation shield under the angiographic table (group 2)
Study: 27317032
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium (100 mg rectally)
Study: 27317032
Drug: Ceftazidime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime (1 g intravenously)
Study: 25611308
Drug: Cis‐UCA excretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cis‐UCA excretion in urine
Study: 21088862
Drug: Cold Water
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Water Immersion Therapy (CWIT) (5°C of temperature [SD ±1°])
Study: 11783762
Drug: Bic/Lac (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bic/Lac (25 mmol/L bicarbonate/15 mmol/L lactate)
Study: 11783762
Drug: Lac (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lac (35 mmol/L lactate)
Study: 7962377
Drug: recFSH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: recFSH with buserelin intranasal spray (4 x 150 micrograms per day) in a short protocol (group II)
Study: 7962377
Drug: recFSH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: recFSH with triptorelin (3.75 mg i.m. in a long protocol) (group IV)
Study: 7962377
Drug: recFSH with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: recFSH with triptorelin (200 micrograms daily s.c. injections) (group V)
Study: 29286560
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy and motivation-based intervention (n=33)
Study: 28043418
Drug: Pralidoxime (PAM)
DrugBank: Pralidoxime (DB00733)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pralidoxime (PAM) treatment guided by APACHE II scores and BuChE activity
Study: 18805335
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment modified based on measurements of fraction of exhaled NO
Study: 18805335
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment based on NAEPP guidelines (Control)
Study: 11346806
Drug: Succimer (lead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succimer (lead chelator), administered orally in up to three 26-day courses
Study: 30120478
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination pill (20 mg telmisartan, 2.5 mg amlodipine, 12.5 mg chlorthalidone)
Study: 30120478
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination pill
Study: 29231403
Drug: Acupuncture based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture based on meridian differentiation, with main acupoints including Neiguan (PC 6), Shuigou (GV 26), Sanyinjiao (SP 6), Fengchi (GB 20), Lianquan (CV 23), Jialianquan (Extra), Jinjin (EX-HN 12), Yuye (EX-HN 13), retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Study: 29231403
Drug: Conventional medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medication and rehabilitation training with control acupuncture points selected 5 cm lateral to the main acupoints, retained for 30 min, once daily, 5 treatments a week for 6 weeks.
Study: 10943584
Drug: Cloricromene (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cloricromene (100 mg orally b.i.d.) for 6 months
Study: 30357610
Drug: Azithromycin eyedrops
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin eyedrops (2.5 mL/25 mg)
Study: 30273332
Drug: Inactivated whole
Normalized name: Inactivated whole Vibrio cholerae Ag
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated whole cell pneumococcal vaccine
Study: 25012429
Drug: Escitalopram 10mg
Normalized name: Escitalopram 10mg Oral tablet
DrugBank: Escitalopram (DB01175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escitalopram 10mg daily for 12 weeks
Study: 21603867
Drug: THERACURMIN 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: THERACURMIN 150 mg
Study: 21603867
Drug: THERACURMIN 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: THERACURMIN 210 mg
Study: 1362888
Drug: Yohimbine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (4 mg three times daily for 3 weeks)
Study: 6147077
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (beta-blockers and diuretics)
Study: 6147077
Drug: Low diuretic
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low diuretic doses
Study: 21304091
Drug: Percutaneous coronary
Normalized name: Glebionis coronaria whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percutaneous coronary intervention (PCI) plus optimal medical therapy (OMT)
Study: 19289623
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/d) plus best supportive care (BSC)
Study: 19289623
Drug: Gefitinib (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib (250 mg/d) plus best supportive care (BSC) in EGFR FISH-positive patients
Study: 11168029
Drug: Weekly oral
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly oral azithromycin, 500 mg (n = 362)
Study: 11168029
Drug: 1.2 MU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2 MU benzathine penicillin G, intramuscularly once (n = 374)
Study: 1454357
Drug: VPB and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: VPB and X‐ray treatment
Study: 1454357
Drug: Second line
Normalized name: Gallus gallus gizzard lining preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second line combined treatment modalities
Study: 6201211
Drug: Consolidation regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation regimen A: continuous infusion of 5-azacytidine, 150 mg/sq m/day for 5 days
Study: 6201211
Drug: Consolidation regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation regimen B: 5-azacytidine plus beta-deoxythioguanosine, 300 mg/sq m/day for 5 days
Study: 6201211
Drug: Consolidation regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation regimen C: cytosine arabinoside, 100 mg/sq m/day intravenously, thioguanine, 100 mg/sq m orally every 12 hr, plus daunorubicin, 10 mg/sq m every 24 hr daily for 5 days
Study: 6201211
Drug: Maintenance regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance regimen D: chemotherapy, 5-day infusion of cytosine arabinoside and 2 days of daunorubicin (same doses as induction) given every 13 wk for 1 yr
Study: 6201211
Drug: Maintenance regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance regimen E: BCG given twice weekly for 1 mo and then monthly for 1 yr
Study: 6201211
Drug: Maintenance regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance regimen F: combination of regimens D and E
Study: 6201211
Drug: Immunotherapy (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy (not specified)
Study: 27590460
Drug: Dexmedetomidine (0.2‐1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2‐1.5 μg/kg/h)
Study: 22148972
Drug: Intrathecal combination
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal combination of cisplatin and OK‐432 with hyperthermotherapy (Group A)
Study: 22148972
Drug: Intrathecal combination
Normalized name: Intrathecal Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal combination of cisplatin and OK‐432 without hyperthermotherapy (Group B)
Study: 18235115
Drug: Imatinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (600 mg/d) in mild liver dysfunction group
Study: 18235115
Drug: Imatinib (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (300 mg/d) in moderate and severe liver dysfunction groups
Study: 18235115
Drug: Imatinib (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (various doses) across all liver dysfunction groups
Study: 18235115
Drug: Imatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (500 mg/d) in mild liver dysfunction group
Study: 16038686
Drug: 400 microg
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microg total dose group (four-100 microg injections over eight weeks)
Study: 16038686
Drug: 2000 microg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2000 microg total dose group (five-400 microg vaccinations over twelve weeks)
Study: 12521655
Drug: Oral contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral contraceptive (30 microg ethynyl estradiol and 150 microg levonorgestrel)
Study: 9279980
Drug: PROG alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROG alone (200 mg PROG twice a day for 3 days)
Study: 9279980
Drug: PROG and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PROG and ATQ (200 mg PROG and 500 mg ATQ twice a day for 3 days)
Study: 28092065
Drug: Celecoxib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (400 mg preoperatively followed by five 200 mg doses every 12 hours)
Study: 28092065
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no anti-inflammatory agents)
Study: 23103551
Drug: Rotigotine treatment
Normalized name: Rotigotine
DrugBank: Rotigotine (DB05271)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rotigotine treatment (up to 3 mg/24 h after an 8-week titration phase)
Study: 21370724
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg once daily for 6 weeks
Study: 12515103
Drug: Trimetazidine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (60 mg)
Study: 12515103
Drug: Isosorbide mononitrate
Normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide mononitrate (60 mg)
Study: 2650729
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml (75 mg) bupivacaine
Study: 2650729
Drug: 15 ml
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 ml (112.5 mg) bupivacaine
Study: 22948416
Drug: Atorvastatin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin plus diet therapy
Study: 21223542
Drug: Neramexane 50
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neramexane 50 mg/day
Study: 21223542
Drug: Neramexane 75
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neramexane 75 mg/day
Study: 21223542
Drug: Neramexane 25
Normalized name: Neramexane
DrugBank: Neramexane (DB04926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neramexane 25 mg/day
Study: 11197651
Drug: EHF therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHF therapy (group 1)
Study: 11197651
Drug: Laser therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser therapy (group 2)
Study: 11197651
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of laser with EHF‐puncture (group 3)
Study: 9120155
Drug: 6 mmol
Normalized name: monobasic potassium phosphate 6 MMOL/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mmol of magnesium/12 mmol of potassium-DL-hydrogenaspartate daily
Study: 25590292
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (Control group) (n = 26)
Study: 20381924
Drug: Intervention by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention by a peer (patient on antiretroviral therapy)
Study: 20381924
Drug: Patients receiving
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients receiving a drug combination including a protease inhibitor
Study: 18753118
Drug: Lopinavir/ritonavir capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir capsules (once or twice daily) with tenofovir DF and emtricitabine (both once daily) for 96 weeks
Study: 12192262
Drug: Selective cyclo-oxygenase
Normalized name: cyclo-D-Serine
DrugBank: Cycloserine (DB00260)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective cyclo-oxygenase inhibitors (COX-II)
Study: 9989555
Drug: Nortriptyline alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nortriptyline alone in a medication clinic (N = 25)
Study: 9989555
Drug: Placebo alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo alone in a medication clinic (N = 22)
Study: 7373080
Drug: Inactivated B/Hong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated B/Hong Kong virus vaccine
Study: 7373080
Drug: Hemagglutination‐inhibiting antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemagglutination‐inhibiting antibody response
Study: 15320956
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg escitalopram daily
Study: 17921381
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin A administered with BCG vaccine at birth
Study: 8712116
Drug: Lidocaine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine (1.5 mg/kg intravenously in 2 minutes)
Study: 8712116
Drug: Procainamide (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procainamide (10 mg/kg intravenously at an injection speed of 100 mg/min)
Study: 20428608
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate (160 mg) with alcohol
Study: 20428608
Drug: Lodenafil carbonate
Normalized name: Lodenafil carbonate
DrugBank: Lodenafil carbonate (DB11927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lodenafil carbonate (160 mg) alone
Study: 18803991
Drug: MON 5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: MON 5-mg tablet QD
Study: 11799078
Drug: L-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine infusion (1 g/min; total 30 g)
Study: 11799078
Drug: Hydralazine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine infusion (control)
Study: 6662724
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dosage of oral aromatic retinoid (75 mg leads to 50 leads to 35 mg; approximately 1 mg/kg/d leads to approximately 0.5 mg/kg/d)
Study: 6662724
Drug: Low initial
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low initial dosage of oral aromatic retinoid (35 mg leads to 50 mg/d leads to 75 mg/d; approximately 0.5 mg/kg/d leads to approximately 1.0 mg/kg/d)
Study: 6662724
Drug: Moderate doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate doses of oral aromatic retinoid (35-60 mg/d; approximately 0.4-0.8 mg/kg/d)
Study: 6662724
Drug: High initial
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High initial dosage of retinoid
Study: 30539282
Drug: Intra-arterial chemotherapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial chemotherapy combined with intravesical chemotherapy (Group A, n=68)
Study: 30539282
Drug: Intravesical chemotherapy
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical chemotherapy alone (Group B, n=135)
Study: 28122931
Drug: 50,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU vitamin D supplements every 2 weeks for 6 months
Study: 25689146
Drug: AFQ056 (25-150
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFQ056 (25-150 mg, twice-daily)
Study: 25022106
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication (aniracetam tablets, 0.2 g twice a day)
Study: 9188228
Drug: Evidence-based periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based periodontal therapy
Study: 3548985
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 to 750 mg daily, increased to a maximum of 1 gm daily during the open-label phase)
Study: 3548985
Drug: Aspirin (2.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (2.6 to 3.9 gm daily)
Study: 21791491
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockade (valsartan 320 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Study: 21791491
Drug: Angiotensin receptor
Normalized name: Angiotensin receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin receptor blockade (valsartan 320 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Study: 21791491
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition (lisinopril 40 mg/day) plus regular sodium diet (200 mmol Na(+)/day)
Study: 21791491
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition (lisinopril 40 mg/day) plus low sodium diet (50 mmol Na(+)/day)
Study: 21791491
Drug: ACE inhibition
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibition (lisinopril 40 mg/day) plus angiotensin receptor blockade (valsartan 320 mg/day)
Study: 11552907
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate 420 mg
Study: 11552907
Drug: Antacid alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid alone
Study: 11552907
Drug: Ranitidine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine plus antacid
Study: 7818585
Drug: roxatidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: roxatidine (150 mg daily) with diclofenac (100 mg daily)
Study: 7818585
Drug: diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (100 mg daily) with placebo
Study: 7818585
Drug: misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: misoprostol (200 micrograms bid) with diclofenac (100 mg daily)
Study: 7818585
Drug: diclofenac (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: diclofenac (100 mg daily) with roxatidine (150 mg daily)
Study: 3276865
Drug: Plasma infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma infusion (P+ group)
Study: 3276865
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy (P- group)
Study: 24018103
Drug: Interaction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction of rs363224 with D2 receptor rs6277 (C957T) polymorphism
Study: 18006647
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of [(14)C]dabigatran etexilate (oral prodrug)
Study: 18006647
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg of [(14)C]dabigatran (i.v. infusion)
Study: 11118564
Drug: Sertaconazole 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertaconazole 300 mg suppository
Study: 11118564
Drug: Econazole 150
Normalized name: oteseconazole 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Econazole 150 mg suppository
Study: 8475322
Drug: Other hypnotics
Normalized name: Other hypnotics and sedatives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other hypnotics
Study: 8475322
Drug: Residual effects
Normalized name: antihemophilic factor, human recombinant residues 743-1636 deleted Injection [Xyntha]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Residual effects of hypnotics
Study: 2417648
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (US) at 1.5 W.cm-2
Study: 2417648
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (US) at 0.1 W.cm-2
Study: 2417648
Drug: Ultrasound therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound therapy (US) at 0.5 W.cm-2
Study: 29788802
Drug: Inhaled menthol
Normalized name: menthol Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled menthol (0.0%, 0.5%, and 3.2%)
Study: 29788802
Drug: Saline and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline and nicotine infusions (0.25 mg and 0.5 mg/70 kg)
Study: 18208463
Drug: 0.1% methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% methylprednisolone aceponate cream + emollients (Group B)
Study: 18208463
Drug: 0.1% methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% methylprednisolone aceponate cream (Group A)
Study: 10753981
Drug: Conventional-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-intensity warfarin therapy (INR 2.2 to 3.5)
Study: 10753981
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin therapy (INR 1.5 to 2.1)
Study: 3555359
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate 50 mg intramuscularly every third week for two years
Study: 3555359
Drug: No anabolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No anabolic steroids (Control)
Study: 25677642
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir plus sitagliptin
Study: 23545909
Drug: Tretinoin 0.025%/clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025%/clindamycin phosphate 1.2% gel in combination with benzoyl peroxide 6% foaming cloth
Study: 23545909
Drug: Tretinoin 0.025%/clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tretinoin 0.025%/clindamycin phosphate 1.2% gel alone